Peri‐operative modulation of cellular immunity in patients with colorectal cancer
暂无分享,去创建一个
J. Primrose | L. Trejdosiewicz | J. Primrose | N. Ambrose | U. Ward | C. Ramsden | N. S. Ambrose | P. H. Nichols | L. K. TREJDOSIEWICZ
[1] J. Primrose,et al. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. , 1992, Cancer research.
[2] P. Guillou,et al. Simplified quantitation of cytotoxicity by integration of specific lysis against effector cell concentration at a constant target cell concentration and measuring the area under the curve. , 1991, Journal of immunological methods.
[3] Timothy A. Springer,et al. Adhesion receptors of the immune system , 1990, Nature.
[4] H. Kirchner,et al. Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies , 1990, The Lancet.
[5] T R Fleming,et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.
[6] J. Sosman,et al. In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies. , 1990, Seminars in oncology.
[7] E. Borden,et al. Lymphokines and cytokines as cancer treatment.Immunotherapy realized , 1990, Cancer.
[8] P. Guillou,et al. Effects of low dose perioperative interferon on the surgically induced suppression of antitumour immune responses , 1988, The British journal of surgery.
[9] Kendall A. Smith,et al. Interleukin-2: inception, impact, and implications. , 1988, Science.
[10] M. Cazzola,et al. Interferons as biologic modulators of hematopoietic cell proliferation and differentiation. , 1988, Haematologica.
[11] R. Fisher,et al. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2. , 1988, Journal of immunology.
[12] J. Dutcher,et al. Phase II Trial of Recombinant Alpha‐2b‐Interferon and Low‐Dose Cyclophosphamide in Advanced Melanoma and Renal Cell Carcinoma , 1988, American journal of clinical oncology.
[13] N. Saijo,et al. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. , 1988, Cancer research.
[14] S. Rosenberg,et al. Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection , 1987, The Journal of experimental medicine.
[15] J. Thompson,et al. Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. , 1987, Cancer research.
[16] P. Bell,et al. Five year results of a randomized trial of adjuvant 5‐fluorouracil and levamisole in colorectal cancer , 1987, The British journal of surgery.
[17] M. Pescatori,et al. Outcome of colorectal cancer , 1987, The British journal of surgery.
[18] W. M. Linehan,et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.
[19] G. Marshall,et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.
[20] A. Chang,et al. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. , 1986, JAMA.
[21] C. McArdle,et al. Occult hepatic metastases in colorectal carcinoma , 1986, The British journal of surgery.
[22] J. Laszlo,et al. Interferon therapy in cancer: from imaginon to interferon. , 1986, Cancer research.
[23] S. Emoto,et al. Do operations facilitate tumor growth? An experimental model in rats. , 1986, Surgery.
[24] P. Guillou,et al. Decreased interleukin−2 production in patients with gastrointestinal cancer , 1986, The British journal of surgery.
[25] Y. Miyauchi,et al. Prevention of growth of metastases in rat liver by perioperative immunoactivation. , 1986, Cancer research.
[26] B. Shenton,et al. The influence of surgical operations on components of the human immune system , 1985, The British journal of surgery.
[27] G. Trinchieri,et al. Immune interferon: a pleiotropic lymphokine with multiple effects. , 1985, Immunology today.
[28] S. Rosenberg,et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.
[29] Kendall A. Smith,et al. T cell growth factor: parameters of production and a quantitative microassay for activity. , 1978, Journal of immunology.
[30] J. Lundy,et al. Halothane, surgery, immunosuppression and artificial pulmonary metastases , 1978 .
[31] J. Ortaldo,et al. Cytotoxic reactivity of human lymphocytes cultured in vitro. , 1977, Journal of immunology.
[32] R. Simmons,et al. Immunodepression after major surgery in normal patients. , 1975, Surgery.
[33] J. Griffiths,et al. CIRCULATING CANCER CELLS DURING EXCISION OF CARINOMAS OF THE RECTUM AND COLON WITH HIGH LIGATION OF THE INFERIOR MESENTERIC VEIN. , 1965, Surgery, gynecology & obstetrics.
[34] D. Morton,et al. Effects of operation on immune response in cancer patients: sequential evaluation of in vitro lymphocyte function. , 1976, Surgery.
[35] A. Bøyum,et al. Separation of leukocytes from blood and bone marrow. Introduction. , 1968 .